{
    "clinical_study": {
        "@rank": "159578", 
        "arm_group": [
            {
                "arm_group_label": "Naltrexone", 
                "arm_group_type": "Experimental", 
                "description": "Arm 1: Naltrexone + SODAS MPH"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Arm 2: Placebo + SODAS MPH"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to a) assess the efficacy of naltrexone in preventing\n      stimulant-induced euphoria in adults with ADHD, b) assess whether naltrexone will interfere\n      with the clinical efficacy of stimulants in treating adults with ADHD, c) assess whether\n      naltrexone will interfere with the effects of stimulants on neurotransmitter activity. We\n      predict that naltrexone will successfully prevent stimulant-induced euphoria without\n      interfering with the ability of stimulants to effectively treat ADHD in adults. This study\n      will be an 8 -week trial with young adults (18-24) with ADHD."
        }, 
        "brief_title": "Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "ADHD", 
            "Stimulant-Induced Euphoria"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion\n\n          1. Male or female adults ages 18-30 years.\n\n          2. A diagnosis of ADHD, per clinical evaluation\n\n          3. At least a minimal likeability response (> 5)  on the DRQ-S  after an initial test\n             dose of 60mg of IR MPH.\n\n          4. Baseline ADHD severity of > 24 on the AISRS.\n\n          5. Able to participate in blood draws and to swallow pills.\n\n          6. Able to understand the nature of the study, to sign an informed consent document and\n             to be considered reliable reporters\n\n        Exclusion\n\n          1. Any current (last month), non-ADHD Axis I psychiatric conditions\n\n          2. Significant current anxiety or depression based on Ham-D > 16, BDI > 19, or Ham-A >\n             21\n\n          3. Any clinically significant chronic medical condition, including cardiovascular\n             disease or hypertension\n\n          4. Clinically significant abnormal baseline laboratory values\n\n          5. I.Q. < 80\n\n          6. Organic brain disorders\n\n          7. Seizures or tics\n\n          8. Pregnant or nursing females\n\n          9. Clinically unstable psychiatric conditions (i.e. suicidal behaviors, psychosis)\n\n         10. Current or recent (within the past year) substance abuse/dependence\n\n         11. Current use of other psychotropic medication(s)\n\n         12. Current or prior adequate treatment with MPH\n\n         13. Known hypersensitivity to methylphenidate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "24 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01673594", 
            "org_study_id": "2012-P-000918"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Naltrexone", 
                    "Placebo"
                ], 
                "description": "Adults with ADHD will receive open-label SODAS MPH", 
                "intervention_name": "SODAS MPH", 
                "intervention_type": "Drug", 
                "other_name": "Ritalin LA"
            }, 
            {
                "arm_group_label": "Naltrexone", 
                "description": "Subjects randomized to the \"active\" double-blind group will receive Naltrexone HCl", 
                "intervention_name": "Naltrexone", 
                "intervention_type": "Drug", 
                "other_name": "Naltrexone HCl"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Naltrexone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "ADHD", 
            "Naltrexone", 
            "SODAS MPH", 
            "Stimulant-Induced Euphoria", 
            "Substance Abuse", 
            "Adults"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "email": "AKOSTER@PARTNERS.org", 
                "last_name": "Ariana Koster", 
                "phone": "617-724-2858"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "rgrossman1@partners.org", 
            "last_name": "Rebecca Grossman, B.S.", 
            "phone": "617-643-1432"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Thomas J Spencer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy (positive, or 'liking' response to stimulant medication) will be assessed by the change in the Drug Rating Questionnaire - Subject (DRQ-S).", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "6 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01673594"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Thomas J. Spencer, MD", 
            "investigator_title": "Associate Chief, Clinical and Research Program,  Pediatric Psychopharmacology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Department of Defense", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}